Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and efficacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 Nominated ORX142 as development candidate; Currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) ...

While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than ...

Executive Leadership Changes - John Crowley CPA has been appointed as the new Chief Financial Officer (CFO) of Centessa Pharmaceuticals, bringing over 20 years of global finance and operational experience in the life sciences industry [5][9] - Gregory Weinhoff MD MBA, the former CFO, has been appointed to the newly created role of Chief Business Officer (CBO), leveraging his extensive business development experience [5][6] - John Crowley's previous roles include CFO at Fusion Pharmaceuticals, Executive Vice President and CFO at Merus Inc, and senior corporate finance positions at Charles River Laboratories, Ironwood Pharmaceuticals, Vertex Pharmaceuticals, and Sunovion Pharmaceuticals [9] - Gregory Weinhoff has over 20 years of business development experience, including roles as CFO at Centessa and Axovant Sciences, and co-founder of Arvelle Therapeutics, which was acquired by Angelini Pharma in 2021 [3] Company Overview and Strategic Focus - Centessa Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering and developing transformational medicines for patients [7] - The company's most advanced programs include a hemophilia program, an orexin agonist program for narcolepsy and sleep-wake disorders, and an immuno-oncology program based on the LockBody® technology platform [7] - The company believes its programs have the potential to change current treatment paradigms and establish new standards of care [7] - Centessa has strengthened its leadership team to position the company for its next phase of growth, with a focus on advancing its clinical programs and maintaining a strong financial framework [1] Business Development and Financial Strategy - The appointment of John Crowley as CFO is expected to enhance the company's financial strategy, operations, and planning, given his deep technical knowledge and experience in the life sciences industry [1][9] - Gregory Weinhoff's new role as CBO will focus on leveraging his experience in developing strategic industry partnerships to bring transformative medicines to patients [6] - The company has emphasized the importance of business development and financial strategy as it transitions into its next chapter of growth [1][6]

Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) has been beaten down lately with too much selling pressure. While the stock has lost 11% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This ...

BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies Global Healthcare Conference Date: June 6, 2024 Location: NY, NY Fireside Chat: 1:00 PM ET Event: Goldman Sachs 45th Annual Global Healthcare Conference Date: June 11, 2024 Lo ...

BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies Global Healthcare Conference Date: June 6, 2024 Location: NY, NY Fireside Chat: 1:00 PM ET Event: Goldman Sachs 45th Annual Global Healthcare Conference Date: June 11, 2024 Lo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40445 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wales 98 ...

Exhibit 99.1 Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 BOSTON and LONDON, May 13, 2024: Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today reported financial results and business highlights for the first quarter ended March 31, 2024. "2024 is off to a strong start for Centessa. Following clearance of our IND, we recently in ...

Core Insights - Centessa Pharmaceuticals reported a strong start to 2024, initiating a Phase 1 clinical trial for ORX750, an orexin receptor 2 agonist for narcolepsy, and plans to share proof-of-concept data later this year [2][5] - The company is advancing three key pipeline programs targeting significant unmet medical needs, including hemophilia B and sleep-wake disorders, supported by a strengthened balance sheet [2][5] - Financial results for Q1 2024 show a net loss of $38.0 million, a decrease from $50.7 million in Q1 2023, with reduced operating expenses [13][17] Recent Highlights - The FDA cleared the IND for ORX750, allowing the initiation of the first-in-human clinical trial [6] - Data from the ongoing Phase 2a study of SerpinPC for hemophilia B showed a 96% reduction in the median annualized bleeding rate [6][10] - The company completed a public offering, raising approximately $107.2 million to support clinical operations [6][13] Anticipated Upcoming Program Milestones - Hemophilia Program: Ongoing registrational studies for SerpinPC, with an interim analysis of the PRESent-2 study planned for 2024 [5][10] - Orexin Agonist Program: Clinical proof-of-concept data for ORX750 expected in the second half of 2024 [5][7] - LockBody Technology Platform: Ongoing Phase 1/2a study of LB101 for solid tumors [5][12] Financial Overview - Cash, cash equivalents, and short-term investments totaled $230.2 million as of March 31, 2024, expected to fund operations into mid-2026 [13][18] - Research and development expenses decreased to $22.7 million in Q1 2024 from $32.8 million in Q1 2023 [13][17] - General and administrative expenses also decreased to $13.4 million in Q1 2024 from $16.1 million in Q1 2023 [13][17]

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares ("ADSs"), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $1 ...